Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 14,761 matching trials from the live ClinicalTrials.gov search.
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Head and Neck Cancer, Non Small Cell Lung Cancer
Interventions
Erlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
Fisons
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York
Conditions
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions
fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Colorectal Cancer, Lung Cancer, Head and Neck Cancer
Interventions
cetuximab and lapatinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Terminated Phase 2 Interventional Results available

Fetal Tracheal Balloon Study in Diaphragmatic Hernia

NCT00966823
Conditions
Diaphragmatic Hernia, Lung Disease
Interventions
Fetal tracheal obstruction with detachable balloon (device)
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Evaluation Comparing Regional Distribution of Ventilation During Lung Expansion Therapy

NCT03083379
Conditions
Ventilation, Breathing, Atelectasis
Interventions
Volumetric Incentive Spirometry, EzPAP® POSITIVE AIRWAY PRESSURE
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Withdrawn No phase listed Observational Accepts healthy volunteers

Chest Computed Tomography (CT) Screening Study With Antibody Testing

NCT01203579
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Lymphoma, Prostate Carcinoma
Interventions
Survivorship Care Plan, Educational Intervention, Questionnaire Administration, Supportive Care
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Terminated Phase 2 Interventional Results available

Metformin in Non Small Cell Lung Cancer (NSCLC)

NCT02285855
Conditions
Lung Cancer
Interventions
Metformin, Placebo, Stereotactic body Radiotherapy (SBRT)
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Breastfeeding Guideline for African-Americans

NCT04476940
Conditions
Covid19, Exclusive Breastfeeding
Interventions
COVID-19 Breastfeeding Support
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers Results available

Shared Decision Making in Rural Primary Care Lung Cancer Screening and Smoking Cessation

NCT04897568
Conditions
Lung Cancer, Smoking Cessation
Interventions
Patient decision aid
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Conditions
Cystic Fibrosis
Interventions
7% NaCl, Amiloride HCl
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
14 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Covid19
Interventions
KELEA Excellerated Water, Water Without an Elevated Level of KELEA
Device
Lead sponsor
Institute of Progressive Medicine
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
South Pasadena, California
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions
Aztreonam Lysine for Inhalation
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
U.S. locations
64
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Conditions
COPD
Interventions
Testosterone Enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Conditions
Pulmonary Hemorrhage, MAPCA - Major Aortopulmonary Collateral Artery
Interventions
Tranexamic Acid
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

Imatinib (QTI571) in Pulmonary Arterial Hypertension

NCT00902174
Conditions
Pulmonary Arterial Hypertension
Interventions
imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
25
States / cities
Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
Conditions
Asthma, Coronary Artery Disease, Diabetes, Hypertension, Congestive Heart Failure
Interventions
Reports, Reports and Notices, Usual care
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
8,422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina